Epidarex Portfolio News

12 Jun

70

New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH

In All, Portfolio

71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs. 0% of eculizumab-treated patients   Detailed results from positive head-to-head Phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria…

03 Jun

52

NodThera Announces Close of $55 Million Series B Financing

In All, Portfolio

Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital  Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including…

21 May

16

Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)

In All, Portfolio

 Submission of New Drug Application (NDA) planned for second half of 2020 following successful pre-NDA meeting with FDA   WALTHAM, Mass., May 21, 2020 – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to submit a New Drug…

28 Apr

46

Apellis Reports Analysis from Phase 1b Geographic Atrophy Study

In All, Portfolio

No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA) Decrease in mean lesion growth in nine patients with bilateral GA consistent with Phase 2 FILLY study Phase 3 DERBY and OAKS studies expected…

27 Apr

34

Encouraging Interim Data from a Phase 1 Clinical Study Evaluating MOv18 IgE in Cancer Patients with Advanced Solid Tumours Presented at the AACR Virtual Annual Meeting

In All, Portfolio

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an IgE antibody as a treatment for advanced cancer London, 27 April 2020 – Epsilogen (formerly IGEM Therapeutics), a global leader…

20 Apr

39

Interim Phase 1 Data Evaluating MOv18 IgE, an Anti-folate Receptor Alpha IgE antibody, in Cancer Patients with Advanced Solid Tumours to be Presented at the AACR Virtual Annual Meeting I

In All, Portfolio

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer  London, 20 April 2020 – Epsilogen (formerly IGEM Therapeutics), a global leader in the development of immunoglobulin E (IgE) antibodies to…

20 Apr

32

Epsilogen Licences MOv18 IgE, an Anti-folate Receptor Alpha IgE Antibody from King’s College London

In All, Portfolio

MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer Investors commit to a further £3 million Series A2 financing of Company   London, 20 April 2020…

10 Feb

34

Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH

In All, Portfolio

Study to be presented at 3rd Global NASH Congress in London, U.K., February 10, 11 Data show, for the first time, that INDY inhibition attenuates diet-induced NASH and mINDY inhibitors may be a novel therapeutic option In a murine NASH model, a small molecule INDY…